REGISTER
MedJ at ESMO 2025 with Dr. Peter Schmid
Recent data bring fresh attention to MedJ at ESMO 2025 with Dr. Peter Schmid. It distills the central data on ESMO, BEGONIA, ORR into a clear account of the article's most important conclusions.

Peter Schmid, Barts Cancer Institute, Queen Mary University, London

Real-time analysis of the BEGONIA trial at ESMO: Dato-DXd combined with immunotherapy demonstrates a 79% ORR in PD-L1-negative advanced TNBC, breaking through immunotherapy limitations and poised to reshape the first-line treatment paradigm.

0
0
Loading